Editas Medicine, Inc.Editas Medicine, Inc.Editas Medicine, Inc.

Editas Medicine, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪198.57 M‬EUR
−2.4210EUR
‪−229.03 M‬EUR
‪31.21 M‬EUR
‪89.11 M‬
Beta (1Y)
2.31
Employees (FY)
246
Change (1Y)
−19 −7.17%
Revenue / Employee (1Y)
Net income / Employee (1Y)

About Editas Medicine, Inc.


CEO
Gilmore O’Neill
Headquarters
Cambridge
Founded
2013
ISIN
US28106W1036
FIGI
BBG00C5XQ159
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Check out other big names from the same industry as 8EM.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange Editas Medicine, Inc. stocks are traded under the ticker 8EM.
We've gathered analysts' opinions on Editas Medicine, Inc. future price: according to them, 8EM price has a max estimate of 5.12 EUR and a min estimate of 0.85 EUR. Watch 8EM chart and read a more detailed Editas Medicine, Inc. stock forecast: see what analysts think of Editas Medicine, Inc. and suggest that you do with its stocks.
8EM reached its all-time high on Jan 11, 2021 with the price of 75.4800 EUR, and its all-time low was 0.8250 EUR and was reached on Apr 9, 2025. View more price dynamics on 8EM chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track Editas Medicine, Inc. financials in yearly and quarterly reports right on TradingView.
Editas Medicine, Inc. is going to release the next earnings report on Nov 10, 2025. Keep track of upcoming events with our Earnings Calendar.
8EM earnings for the last quarter are −0.53 EUR per share, whereas the estimation was −0.33 EUR resulting in a −61.31% surprise. The estimated earnings for the next quarter are −0.25 EUR per share. See more details about Editas Medicine, Inc. earnings.
Editas Medicine, Inc. revenue for the last quarter amounts to ‪3.04 M‬ EUR, despite the estimated figure of ‪1.96 M‬ EUR. In the next quarter, revenue is expected to reach ‪4.25 M‬ EUR.
8EM net income for the last quarter is ‪−45.19 M‬ EUR, while the quarter before that showed ‪−70.33 M‬ EUR of net income which accounts for 35.75% change. Track more Editas Medicine, Inc. financial stats to get the full picture.
No, 8EM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 3, 2025, the company has 246 employees. See our rating of the largest employees — is Editas Medicine, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Editas Medicine, Inc. EBITDA is ‪−130.79 M‬ EUR, and current EBITDA margin is −721.39%. See more stats in Editas Medicine, Inc. financial statements.
Like other stocks, 8EM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Editas Medicine, Inc. stock right from TradingView charts — choose your broker and connect to your account.